Navigation Links
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
Date:11/9/2009

MIAMI, Nov. 9 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies. These results were presented in poster sessions at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Miami Beach, FL.

In a poster presentation titled, "Treatment of Ocular Itching with Bepotastine Besilate Ophthalmic Solution 1.5% for Subjects with More Severe Itching Response in a Conjunctival Allergen Challenge (CAC) Clinical Model of Allergic Conjunctivitis," integrated results from two Phase 3 studies demonstrated Bepreve 1.5% was as effective in suppressing ocular itching in patients with more severe itching as in patients with all grades of ocular itching. A total of 157 patients were enrolled in two 7-week, masked, randomized, placebo-controlled CAC clinical studies (1 single site, 1 multi-site). 113 patients exhibited bilateral ocular itching grades greater than or equal to 3 at screening during study visit 2. Individuals were assessed at 15 minutes, 8 hours, or 16 hours following instillation at study visits spaced 2 weeks apart during the enrollment period. The difference in mean itching grades (placebo-active) for the more severely affected subjects was within plus or minus 0.1 unit of the differences for the entire intent-to-treat (ITT) population. Authors of the poster were J. I. Williams, J. A. Gow, P. J. Gomes, M. B. Abelson, and T. R. McNamara.

ISTA presented more results from CAC clinical trials with Bepreve 1.0% and 1.5% in the following poster presentations at the same meeting:

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Nasal Congestion with Rapid Onset in a Clinical Model of Allergic Conjunctivitis


'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
2. DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
4. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
5. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
6. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
11. VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 Regen BioPharma, Inc. (OTCBB: RGBP) ... novel means of delivering its patented (US Patent ... tumors utilizing a clinically approved formulation as delivery ... with gene silencing therapeutics in which the gene ... whole body.  By utilizing a local delivery system, ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , Aug. ... ; EURONEXT: SAN) and the life sciences team at ... care and outcomes for people with type 1 and ... treatments and devices with Google,s expertise in analytics, miniaturized ... explore how to improve diabetes care by developing new ...
(Date:8/31/2015)...  Qualcomm Incorporated (NASDAQ: QCOM ) today ... is collaborating with Davita Healthcare Partners and ... by Qualcomm Life,s 2net™ Device Connectivity Platform and ... informed interventions and better management of at-risk populations. ... Connect 2015 ecosystem conference taking place ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 7, 2011  Tethys Bioscience has entered into an agreement ... employers measurably flatten the trajectory of their healthcare trends ... their employee populations. The agreement allows ACAP Health to ... as a component of its disease intervention programs. The ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... of the granting of a European patent with broad ... diketopiperazine which is the active ingredient of Ampion™.  The ...
Cached Medicine Technology:Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™ 2
(Date:9/1/2015)... ... September 01, 2015 , ... ... established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. It is ... alliance is dedicated to the provision of quality addiction treatment and the ...
(Date:9/1/2015)... ... September 01, 2015 , ... Award-winning adult ... artists about their experiences of female beauty, women’s emotions, fertility, female violence and ... as well as their relationships with other men, documenting how the power balance ...
(Date:9/1/2015)... ... ... Routines… every family has them. Whether it’s a morning routine, meal time ... and children too. Here are three reasons why routines can be beneficial for a ... a routine is implemented into a child’s schedule, they are able to anticipate what ...
(Date:9/1/2015)... CO. (PRWEB) , ... September 01, 2015 , ... September ... and product manufacturers use safety labels and stickers to keep little ones' safety top ... year Baby Safety Month has a particular focus. According to the JPMA's Baby Safety ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... leading retailer of professional hair salons. This highly anticipated partnership between Curly Hair ... Curl Keeper™ Styling Collection. Founder Jonathan Torch and the Curly Hair Solutions™ team ...
Breaking Medicine News(10 mins):Health News:MAP Health Management Launches the MAP Recovery Network 2Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2
... , ANN ARBOR, Mich., Aug. 7 ... for drug and disease reference, patient education, and consumer health information ... , Price Chopper, in business for more than ... continues to grow in this region. It operates pharmacies in 68 ...
... relief but should be reserved for worst cases, researchers say, ... of a corticosteroid, given along with antibiotics, can relieve severe ... a new study suggests. , "In people with severe sore ... in relieving pain in 24 and 48 hours," said researcher ...
... , , , ... announced that it has been notified that a purported class action ... the Northern District of Illinois against the Company and certain of ... and February 13, 2008 the Company failed to disclose certain facts ...
... one of the errors most frequently confirmed in the ... Vinz and Johann Neu of the Arbitration Board of ... edition of Deutsches rzteblatt International (Dtsch Arztebl ... expert reports and rulings in 189 panel proceedings from ...
... , ... 6, 2009 in the New England Journal of Medicine claim to demonstrate that vertebroplasty, a ... in the field, this is incorrect, as both studies actually demonstrate a significant improvement in ... ...
... in financing, delivery of care are needed to close ... -- Even if Congress extends health coverage to the ... everyone will have access to care -- unless payment ... experts say. , Significantly expanding coverage without reforming health-care ...
Cached Medicine News:Health News:Price Chopper Supermarkets Deploy Micromedex Solutions From Thomson Reuters as Key Component of Its Patient-Centered Care Initiatives 2Health News:Steroid Can Ease Severe Sore Throat 2Health News:Steroid Can Ease Severe Sore Throat 3Health News:Allscripts Notified of Purported Class Action Lawsuit 2Health News:Allscripts Notified of Purported Class Action Lawsuit 3Health News:Out of court settlement of malpractice claims: Incorrect treatment of bone fractures in children 2Health News:Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading: Studies Actually Show it is Effective at Reducing Pain 2Health News:Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading: Studies Actually Show it is Effective at Reducing Pain 3Health News:Expanding Health Coverage May Not Improve Access 2Health News:Expanding Health Coverage May Not Improve Access 3
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: